Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Cardiotoxicity 6Lymphoma, Non-Hodgkin 4Lymphoma 3Breast Neoplasms 3Prostatic Neoplasms 2Multiple Myeloma 2Leukemia 2Cardiovascular Diseases 2Small Cell Lung Carcinoma 1Obesity 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Metastatic Solid Tumors 1Metabolic Syndrome 1Melanoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Effusion 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lung Neoplasms 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Heart Failure 1Epstein-Barr Virus Infections 1

Interventions

Injections 2Infusions, Intravenous 2tislelizumab 1sacituzumab govitecan 1bintrafusp alfa protein, human 1Tomography, X-Ray Computed 1Platinum 1Nivolumab 1Ipilimumab 1Iodine-125 1Electrocardiography 1Echocardiography 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Solid Tumors × Echocardiography × 1 year × Clear all
NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
31 enrolled 20 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡